EUVIMEDEUVIMED entdecken
LeserbriefOpen Access

Efficay of cefiderocol as salvage therapy in tricuspid endocarditis due to multidrug-resistant Acinetobacter baumannii during end-stage renal disease

Antonio Mastroianni iD, Sonia Greco iD

Revista Española de Quimioterapia · 29.09.2026 · 39 (5) · 468

DOI: 10.37201/req/207.2026 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Revista Española de Quimioterapia, online erschienen am 21.09.2026. Verfasst von Antonio Mastroianni und 1 weiteren Autor:innen. Beteiligte Einrichtung: Infectious and Tropical Diseases Unit, Azienda Ospedaliera di Cosenza, Cosenza, Italy. antoniomastroianni@yahoo.it. Der Volltext ist frei in PubMed Central verfügbar.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Autor:innen und Institutionen

  • Infectious and Tropical Diseases Unit, Azienda Ospedaliera di Cosenza, Cosenza, Italy. antoniomastroianni@yahoo.it.
  • Infectious and Tropical Diseases Unit, Azienda Ospedaliera di Cosenza, Cosenza, Italy.

ORCID-Profile: Antonio Mastroianni, Sonia Greco

Zitieren

APA

Mastroianni, A., & Greco, S. (2026). Efficay of cefiderocol as salvage therapy in tricuspid endocarditis due to multidrug-resistant Acinetobacter baumannii during end-stage renal disease. Revista Española de Quimioterapia, 39(5), 468. https://doi.org/10.37201/req/207.2026

Vancouver

Mastroianni A, Greco S. Efficay of cefiderocol as salvage therapy in tricuspid endocarditis due to multidrug-resistant Acinetobacter baumannii during end-stage renal disease. Revista Española de Quimioterapia. 2026;39(5):468. doi:10.37201/req/207.2026

BibTeX
@article{Mastroianni2026,
  author = {Mastroianni, Antonio and Greco, Sonia},
  title = {Efficay of cefiderocol as salvage therapy in tricuspid endocarditis due to multidrug-resistant Acinetobacter baumannii during end-stage renal disease},
  journal = {Revista Española de Quimioterapia},
  year = {2026},
  volume = {39},
  number = {5},
  pages = {468},
  doi = {10.37201/req/207.2026}
}
Kostenlos starten →